IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research.
A big thank you to everyone we met at EAU26! We received many insightful inputs that will guide our ongoing development and help us stay focused on what matters most: delivering better, faster, and more accessible diagnostics for patients.
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q4’25 results – February 26, 2026 Q4 Interview: Redeye talks with CEO Anders Hultman
Last week, IDL Diagnostics participated as an exhibitor at WHX Labs Dubai together with concile as part of the recently announced joint venture. The main focus is on delivering multiple biomarkers across different POC reader configurations and supporting infection,...
We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.
